Chester County News and Community Website
WILMINGTON, DE — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) said it has received written confirmation from the U.S. Food and Drug Administration supporting a path toward approval of its depression treatment …
NRx Says FDA Will Review NRX-100 Without New Trials Read More WILMINGTON, DE — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) announced it has appointed Joshua C. Brown, MD, PhD, as chief medical innovation officer to support the company’s development of treatments for …
NRx Pharmaceuticals Appoints Joshua C. Brown Chief Medical Innovation Officer Read More WILMINGTON, DE — NRx Pharmaceuticals Inc. (Nasdaq: NRXP) said it received guidance from the U.S. Food and Drug Administration that could allow the company to file a New Drug Application …
NRx Reports FDA Guidance on NRX-100 Approval Path Read More WILMINGTON, DE — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) said it will hold its 2025 annual meeting of stockholders on March 23, 2026, at 10:00 a.m. Eastern Time in a virtual-only …
NRx Pharmaceuticals (NASDAQ: NRXP) Sets Virtual Annual Meeting for March Read More WILMINGTON, DE — NRx Pharmaceuticals, Inc. said it has secured Fast Track designation from the U.S. Food and Drug Administration for NRX-100, a preservative-free ketamine formulation aimed at treating suicidal …
FDA Fast Track Puts Ketamine-Based Therapy in Spotlight for Suicide Care Read More WILMINGTON, DE & MUNICH, Germany — NRx Pharmaceuticals Inc. (Nasdaq: NRXP) and neurocare Group AG have announced a partnership to build a nationwide network of clinics offering integrated neuroplastic care …
A High-Stakes Alliance Aims to Standardize Mental Health Care at Scale Read More WILMINGTON, DE — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) expanded its development plan for NRX-101, amending its Investigational New Drug application to study the drug in combination with Transcranial Magnetic Stimulation …
NRx Eyes Faster Commercial Path as NRX-101 Moves Into TMS-Enhanced Depression Treatment Read More WILMINGTON, DE — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) said the U.S. Food and Drug Administration has accepted its Abbreviated New Drug Application for KETAFREE, a preservative-free intravenous ketamine product that …
NRx’s Preservative-Free Ketamine Reaches FDA Review as Company Targets 2026 Launch Read More WILMINGTON, DE — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) reported third-quarter financial results and detailed a rapidly accelerating push into new psychiatric treatments, expanded clinic operations, and a dual-path regulatory strategy …
NRx Pushes Fast-Track Depression Treatments as Losses Mount and Clinics Expand Read More WILMINGTON, DE — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) has re-filed its Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for KETAFREE™, a preservative-free intravenous ketamine …
NRx Re-Files FDA Application for Preservative-Free IV Ketamine Read More